Track market-moving stories before they get noisy

Hsbc Holdings PLC grew its holdings in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) by 11.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,116,625 shares of the utilities provider’s stock after buying an additional 113,888 shares during the period. Hsbc Holdings PLC owned 0.17% of CenterPoint Energy worth $49,316,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Beacon Pointe Advisors LLC acquired a new stake in CenterPoint Energy in the 2nd quarter valued at approximately $606,000. Kimelman & Baird LLC acquired a new position in CenterPoint Energy during the 2nd quarter worth $62,000. Pin Oak Investment Advisors Inc. acquired a new position in CenterPoint Energy during the 2nd quarter worth $44,000. Rakuten Investment Management Inc. bought a new position in shares of CenterPoint Energy in the second quarter worth $4,789,000. Finally, Empowered Funds LLC acquired a new position in shares of CenterPoint Energy during the second quarter valued at $1,559,000. 91.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets A number of equities research analysts recently weighed in on CNP shares. Wall Street Zen upgraded shares of CenterPoint Energy from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. BTIG Research assumed coverage on shares of CenterPoint Energy in a research report on Tuesday, June 30th. They issued a “neutral” rating for the company. Wolfe Research reissued an “outperform” rating and set a $49.00 target price on shares of CenterPoint Energy in a research note on Wednesday, July 29th. KeyCorp dropped their price target on shares of CenterPoint Energy from $47.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, July 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of CenterPoint Energy from $45.00 to $47.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Nine equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.36.

Get Our Latest Stock Report on CNP CenterPoint Energy Price Performance NYSE CNP opened at $39.63 on Tuesday. The stock has a market capitalization of $26.11 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.62 and a beta of 0.46. CenterPoint Energy, Inc. has a 1 year low of $37.13 and a 1 year high of $45.26. The business’s fifty day moving average is $41.79 and its two-hundred day moving average is $42.50. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.97 and a current ratio of 1.12.

CenterPoint Energy (NYSE:CNP – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.03. The business had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.12 billion. CenterPoint Energy had a return on equity of 11.10% and a net margin of 11.61%.During the same period last year, the company posted $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. On average, research analysts forecast that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current fiscal year.

CenterPoint Energy Increases Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Thursday, August 20th will be issued a dividend of $0.24 per share. This is a positive change from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, August 20th. CenterPoint Energy’s dividend payout ratio (DPR) is currently 56.47%.

CenterPoint Energy Company Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Recommended Stories Five stocks we like better than CenterPoint Energy 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

Beacon Pointe Advisors LLC acquired a new position in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,763 shares of the utilities provider’s stock, valued at approximately $606,000.

A number of other hedge funds have also modified their holdings of CNP. Kimelman & Baird LLC bought a new stake in CenterPoint Energy in the 2nd quarter valued at approximately $62,000. Pin Oak Investment Advisors Inc. bought a new position in shares of CenterPoint Energy during the 2nd quarter worth approximately $44,000. Rakuten Investment Management Inc. bought a new position in shares of CenterPoint Energy during the 2nd quarter worth approximately $4,789,000. Empowered Funds LLC acquired a new stake in shares of CenterPoint Energy in the second quarter valued at approximately $1,559,000. Finally, United Capital Financial Advisors LLC acquired a new stake in shares of CenterPoint Energy in the second quarter valued at approximately $868,000. 91.77% of the stock is currently owned by institutional investors.

CenterPoint Energy Stock Performance Shares of CNP opened at $39.69 on Tuesday. The firm has a 50-day moving average of $42.25 and a 200-day moving average of $42.59. CenterPoint Energy, Inc. has a one year low of $36.60 and a one year high of $45.26. The company has a market cap of $26.14 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 2.32 and a beta of 0.46. The company has a debt-to-equity ratio of 1.95, a current ratio of 1.12 and a quick ratio of 0.97.

CenterPoint Energy (NYSE:CNP – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.03. CenterPoint Energy had a net margin of 11.61% and a return on equity of 11.10%. The company had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same period in the previous year, the business earned $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. As a group, equities analysts forecast that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current year. CenterPoint Energy Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Thursday, August 20th will be paid a dividend of $0.24 per share. The ex-dividend date is Thursday, August 20th. This represents a $0.96 annualized dividend and a dividend yield of 2.4%. This is an increase from CenterPoint Energy’s previous quarterly dividend of $0.23. CenterPoint Energy’s dividend payout ratio is presently 56.47%.

Analyst Ratings Changes CNP has been the subject of several recent research reports. KeyCorp reduced their target price on shares of CenterPoint Energy from $47.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, July 23rd. Weiss Ratings reissued a “buy (b)” rating on shares of CenterPoint Energy in a research report on Monday, June 15th. Jefferies Financial Group set a $50.00 price objective on shares of CenterPoint Energy in a research note on Thursday, June 18th. Truist Financial decreased their price objective on CenterPoint Energy from $48.00 to $46.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, BMO Capital Markets lowered their target price on CenterPoint Energy from $48.00 to $47.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 22nd. Nine analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.36.

Get Our Latest Research Report on CNP

CenterPoint Energy Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

See Also Five stocks we like better than CenterPoint Energy Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

 | Source: Ascendis Pharma

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital.

“This long-term data reinforces the benefits seen in clinical trials of once-weekly TransCon CNP, which have ranged from durable improvements in height to improvements in lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning – with a safety and tolerability profile similar to placebo and a low rate of injection site reactions,” said Aimee Shu, Executive Vice President, Chief Medical Officer at Ascendis Pharma. “The results align with improvements in health-related quality of life identified as important to the achondroplasia community and we look forward to sharing them with experts focused on advancing treatment of individuals living with skeletal dysplasia.”

Ascendis presentations at ISDS 2026 include:

ORAL PRESENTATIONFriday
August 28
10:00-10:15am
Session 4Abstract #45
Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension
Presented by Carlos Bacino, M.D.POSTER Wednesday – Saturday
August 26-29
Poster BoardsNumber Needed to Harm Analysis for Injection Site Reactions When Indirect Treatment Comparison (ITC) Is Not Suitable
Authors: Manoj Chevli et al   About TransCon CNP
TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ planned oral presentation and poster at ISDS 2026, (ii) the benefits seen in clinical trials of once-weekly TransCon CNP, including durable improvements in height, lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning, (iii) the safety and tolerability profile of TransCon CNP, including a profile similar to placebo and a low rate of injection site reactions, (iv) the potential for the reported results to align with improvements in health-related quality of life identified as important to the achondroplasia community, (v) Ascendis’ clinical development activities, including the ApproaCH Trial open-label extension, (vi) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (vii) Ascendis’ use of TransCon to create new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YUVIWEL® are trademarks owned by the Ascendis Pharma group. © August 2026 Ascendis Pharma A/S. 

  Investor Contacts:Media Contact:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875  

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.

While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.

Headquartered in Houston, CenterPoint Energy (CNP - Free Report) is a Utilities stock that has seen a price change of 2.48% so far this year. Currently paying a dividend of $0.24 per share, the company has a dividend yield of 2.44%. In comparison, the Utility - Electric Power industry's yield is 3.18%, while the S&P 500's yield is 1.32%.

Looking at dividend growth, the company's current annualized dividend of $0.96 is up 9.1% from last year. Over the last 5 years, CenterPoint Energy has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.33%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. CenterPoint's current payout ratio is 48%, meaning it paid out 48% of its trailing 12-month EPS as dividend.

Looking at this fiscal year, CNP expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $1.91 per share, representing a year-over-year earnings growth rate of 8.52%.

From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. But, not every company offers a quarterly payout.

High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. That said, they can take comfort from the fact that CNP is not only an attractive dividend play, but also represents a compelling investment opportunity with a Zacks Rank of #2 (Buy).

Barrow Hanley Mewhinney & Strauss LLC bought a new position in CenterPoint Energy, Inc. (NYSE:CNP – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,420,488 shares of the utilities provider’s stock, valued at approximately $150,638,000. Barrow Hanley Mewhinney & Strauss LLC owned 0.52% of CenterPoint Energy as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Haverford Trust Co acquired a new position in CenterPoint Energy in the 2nd quarter worth about $393,000. Bank of Nova Scotia acquired a new stake in shares of CenterPoint Energy in the second quarter worth $9,870,000. Elevation Point Wealth Partners LLC bought a new stake in CenterPoint Energy during the second quarter valued at about $1,646,000. Daiichi Life Insurance Co. Ltd. acquired a new stake in CenterPoint Energy in the 2nd quarter valued at approximately $1,276,000. Finally, Commerce Bank bought a new position in CenterPoint Energy during the second quarter worth $3,136,000. 91.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth A number of brokerages recently commented on CNP. Truist Financial cut their target price on CenterPoint Energy from $48.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Morgan Stanley dropped their price target on CenterPoint Energy from $40.00 to $39.00 and set an “equal weight” rating for the company in a report on Friday. KeyCorp reduced their target price on shares of CenterPoint Energy from $47.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, July 23rd. JPMorgan Chase & Co. raised their price target on CenterPoint Energy from $45.00 to $47.00 and gave the company a “neutral” rating in a report on Thursday, July 16th. Finally, Wolfe Research reaffirmed an “outperform” rating and set a $49.00 target price on shares of CenterPoint Energy in a report on Wednesday, July 29th. Nine research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.36.

Get Our Latest Stock Report on CNP CenterPoint Energy Stock Up 0.1% NYSE:CNP opened at $38.81 on Monday. The firm has a market capitalization of $25.56 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 2.30 and a beta of 0.46. CenterPoint Energy, Inc. has a twelve month low of $36.60 and a twelve month high of $45.26. The stock’s 50 day moving average price is $42.69 and its two-hundred day moving average price is $42.63. The company has a quick ratio of 0.97, a current ratio of 1.12 and a debt-to-equity ratio of 1.95.

CenterPoint Energy (NYSE:CNP – Get Free Report) last issued its earnings results on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. CenterPoint Energy had a net margin of 11.61% and a return on equity of 11.10%. The company had revenue of $2.15 billion for the quarter, compared to analysts’ expectations of $2.12 billion. During the same period in the prior year, the firm earned $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. Equities research analysts expect that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current fiscal year.

CenterPoint Energy Increases Dividend The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Thursday, August 20th will be given a dividend of $0.24 per share. This is a positive change from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 20th. CenterPoint Energy’s dividend payout ratio (DPR) is currently 56.47%.

CenterPoint Energy Company Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Featured Articles Five stocks we like better than CenterPoint Energy VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

21.8.2026 22:09

Zámořské akciové trhy během dnešního obchodování vzrostly a zakončily volatilní týden v kladných číslech. Podporu trhům poskytla příznivá makroekonomická data ukazující nejrychlejší tempo růstu podnikatelské aktivity v USA za poslední čtyři roky. Index Dow Jones si připsal 0,98 % na 53277,01 bodu, širší S&P 500 vzrostl o 0,43 % na 7674,36 bodu a technologický Nasdaq Composite zpevnil o 0,43 % na 26180,46 bodu. Z jednotlivých odvětví indexu S&P 500 dosáhly nejvyšších zisků základní materiály s růstem o 2,2 %, následované zdravotní péčí o 1,3 % a zbytnou spotřebou o 1 %. Naopak nejvýraznější pokles zaznamenaly utility, které ztratily 2,3 %, zatímco energie a reality odepsaly 0,2 % a 0 %. Mezi jednotlivými tituly výrazně posílila společnost Robinhood Markets (HOOD) o 14 %, dále pak Moderna (MRNA) o 8,9 %, Freeport-McMoRan (FCX) o 7,7 %, Coinbase Global (COIN) o 8,2 % a Albemarle Corp (ALB) o 6,8 %. Největší propad naopak postihl společnost Marvell Technology (MRVL), jež oslabila o 5,6 %, a nedařilo se ani firmám Sempra (SRE) se ztrátou 5,1 %, Edison International (EIX) o 4,1 %, American Electric Power (AEP) o 3,8 % a CenterPoint Energy (CNP) s poklesem o 3,6 %. Na komoditních trzích mírně vzrostla cena severoamerické lehké ropy WTI o 0,2 % na 87 dolarů za barel, zatímco spotové zlato posílilo o 2,4 % na 4624,69 dolaru za unci. Americký dolar celkově mírně oslabil. Výnos desetiletých amerických vládních dluhopisů vzrostl o tři bazické body na 4,73 %. Výrazný růst zaznamenal bitcoin, jehož cena stoupla o 6,1 % na 77086,77 dolaru.

Index Dow Jones +0,98 % na 53277,01 b.
S&P 500 +0,43 % na 7674,36 b.
Nasdaq Composite +0,43 % na 26180,46 b.

Index S&P 500 +0,43 % na 7674,36 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Základní materiály +2,2 % Utility -2,3 % Zdravotní péče +1,3 % Energie -0,2 % Finanční sektor +1 % Reality 0 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Robinhood Markets (HOOD) +14 % Marvell Technology (MRVL) -5,6 % Moderna (MRNA) +8,9 % Sempra (SRE) -5,1 % Coinbase Global (COIN) +8,2 % Edison International (EIX) -4,1 % Freeport-McMoRan (FCX) +7,7 % American Electric Power (AEP) -3,8 % Albemarle Corp (ALB) +6,8 % CenterPoint Energy (CNP) -3,6 %
Daniel Marván
Fio banka, a.s.
Prohlášení

Company outlines opportunity for more than $5 billion in potential savings for Texas electric
customers over the next decade driven by additional large load customers paying for more
infrastructure charges

CenterPoint committed to advancing Governor Abbott's call for greater transparency and clear
standards for new data centers and the requirements established by 2025's Senate Bill 6 to
safeguard Texans

CenterPoint's Greater Houston customers continue to have the lowest infrastructures charges of
any of the investor-owned electric utilities in the state

, /PRNewswire/ -- Today, as part of CenterPoint Energy's ongoing commitment to prioritize customer affordability, the company announced a historic Customer Savings Initiative that offers the opportunity to save Texas electric customers, including CenterPoint's Greater Houston residential, small & medium businesses, and commercial customers, more than $5 billion over the next decade. CenterPoint is committed to advancing Texas Governor Greg Abbott's recent call for greater transparency from developers and the need to set clear standards for the development, construction, and on-going operation of data centers in the state and is already working with customers to meet that call. The company fully supported the customer protections established by Senate Bill 6 in 2025 and has implemented these requirements for these new large load projects included as part of the Customer Savings Initiative.

CenterPoint's newly announced savings initiative, which builds on the company's successful efforts to keep electric rates the lowest of any Texas investor-owned electric transmission and distribution utility, is driven by the planned addition of up to 14 new gigawatts of ERCOT eligible base load and studied load projects. The additional load from these projects would translate into customer savings over the next decade through more and larger customers paying more of the share of fixed grid costs.

"Greater Houston has long been the energy capital of the world, but today it is the home of one of the most diverse economic regions anywhere in the nation. These new projects would help us deliver growth, innovation, and customer savings. We have a once-in-a-generation opportunity to generate historic levels of customer savings of more than $5 billion statewide by leveraging new investment in large projects to build a more affordable, reliable and resilient electric grid for millions of customers. These infrastructure investments and economic development opportunities have the potential to save current customers billions, while also creating jobs and generating millions in local tax revenue to improve our local schools and community public services," said Jason Wells, Chairman & Chief Executive Officer of CenterPoint Energy.

Customer Savings Initiative: An Enduring Commitment to Affordability

The company's Customer Savings Initiative represents CenterPoint's plan to promote greater customer savings and strengthen energy affordability over the coming decade. The pillars of this initiative include the following:

$5 Billion in Statewide Savings: The projected addition of up to 14 gigawatts of eligible base load and studied load projects, along with CenterPoint's continued effort facilitate more growth across the Greater Houston region will help CenterPoint meet future demand from industrial, business and residential growth and will translate into real savings for hard-working Texans. Strengthening the Commitment to Keep Rates Stable: For the past decade, the portion of the customer bill which covers investments in CenterPoint infrastructure has remained stable and increased by just over 1 percent per year (2014-2025), well below the national inflation rate over the same time period. Today, CenterPoint's Greater Houston customers pay the lowest cost per kilowatt hour than any of the other Texas investor-owned electric transmission and distribution utilities. The company achieved this through increasing the customer base, more efficiently financing operations and reducing costs. The addition of new base load will help CenterPoint continue to keep rates stable and affordable over the next decade, providing real energy savings to millions of Texas electric customers.  Committed to National Ratepayer Protection Pledge: CenterPoint signed and supported the recently announced National "Ratepayer Protection Pledge" that would prioritize customer affordability, while enabling private investment responsibly to strengthen the grid and connect more large load customers. Committed to Continuing to Work with Governor Greg Abbott, Legislators, and other state Leaders to Establish Greater Transparency and Clear standards: The framework implemented by the Texas Legislature and the call for greater clarity and clear standards called for by Governor Abbott will help drive continued economic growth, strengthen grid reliability and resiliency, and ensure that new large customers pay the costs associated with connecting and powering their business. CenterPoint stands behind that framework and is partnering with large customers who share that commitment. About CenterPoint Energy, Inc. 

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of June 30, 2026, the company owned approximately $48.3 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

Through expanding customer connections and making critical investments across the service area, the company is delivering on its mission to build an affordable, future-ready energy grid for its nearly 2.9 million Greater Houston customers.

Forward-Looking Statement
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon assumptions of management which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. Actual events and results may differ materially from those expressed or implied by these forward-looking statements. Any statements in this news release regarding future events, such as the potential for large load customer projects and the benefits therefrom (including customer savings, tax revenue and related benefits, and jobs creation), the reliability and resiliency of the electric grid, and any other statements that are not historical facts are forward-looking statements. Each forward-looking statement contained in this news release speaks only as of the date of this release. Important factors that could cause actual results to differ materially from those indicated by the provided forward-looking information include risks and uncertainties relating to: (1) business strategies and strategic initiatives involving CenterPoint Energy or its industry; (2) CenterPoint Energy's ability to fund and invest planned capital, and the timely recovery of its investments; (3) financial market and general economic conditions; (4) the timing and impact of future regulatory, legislative and political actions or developments; and (5) other factors, risks and uncertainties discussed in CenterPoint Energy's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and CenterPoint's Quarterly Report on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 and other reports CenterPoint Energy or its subsidiaries may file from time to time with the Securities and Exchange Commission.

Media Contact: [email protected]

SOURCE CenterPoint Energy, Inc

Posted by Defense World Staff on Aug 8th, 2026

Empowered Funds LLC grew its holdings in CenterPoint Energy, Inc. (NYSE:CNP – Free Report) by 95.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 33,996 shares of the utilities provider’s stock after buying an additional 16,600 shares during the quarter. Empowered Funds LLC’s holdings in CenterPoint Energy were worth $1,467,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Capital Research Global Investors raised its holdings in CenterPoint Energy by 1.1% in the 4th quarter. Capital Research Global Investors now owns 20,941,909 shares of the utilities provider’s stock worth $802,916,000 after acquiring an additional 235,346 shares during the last quarter. Ilmarinen Mutual Pension Insurance Co bought a new position in CenterPoint Energy during the fourth quarter valued at approximately $3,834,000. Principal Financial Group Inc. boosted its holdings in CenterPoint Energy by 6.9% in the fourth quarter. Principal Financial Group Inc. now owns 962,624 shares of the utilities provider’s stock worth $36,907,000 after purchasing an additional 61,740 shares during the last quarter. Artemis Investment Management LLP boosted its holdings in CenterPoint Energy by 96.0% in the fourth quarter. Artemis Investment Management LLP now owns 1,595,867 shares of the utilities provider’s stock worth $61,186,000 after purchasing an additional 781,849 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of CenterPoint Energy by 5.2% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,367,838 shares of the utilities provider’s stock valued at $52,976,000 after purchasing an additional 67,037 shares during the period. 91.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In Several research firms have recently commented on CNP. Morgan Stanley set a $40.00 price objective on CenterPoint Energy in a research note on Wednesday, July 22nd. Bank of America lifted their target price on shares of CenterPoint Energy from $42.00 to $44.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. BTIG Research started coverage on CenterPoint Energy in a research report on Tuesday, June 30th. They set a “neutral” rating for the company. Jefferies Financial Group set a $50.00 price target on CenterPoint Energy in a research note on Thursday, June 18th. Finally, Truist Financial reduced their price target on shares of CenterPoint Energy from $48.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $45.57.

Read Our Latest Research Report on CNP

CenterPoint Energy Stock Performance Shares of CNP opened at $40.67 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.97 and a debt-to-equity ratio of 1.95. The firm has a market cap of $26.79 billion, a PE ratio of 23.92, a P/E/G ratio of 2.41 and a beta of 0.46. CenterPoint Energy, Inc. has a 12 month low of $36.60 and a 12 month high of $45.26. The stock has a fifty day moving average price of $43.07 and a 200-day moving average price of $42.55.

CenterPoint Energy (NYSE:CNP – Get Free Report) last issued its earnings results on Tuesday, July 28th. The utilities provider reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. The firm had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.12 billion. CenterPoint Energy had a return on equity of 11.10% and a net margin of 11.61%.During the same quarter in the prior year, the firm earned $0.29 earnings per share. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. Equities research analysts predict that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current fiscal year.

CenterPoint Energy Increases Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Thursday, August 20th will be paid a $0.24 dividend. This is an increase from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, August 20th. CenterPoint Energy’s payout ratio is 54.12%.

CenterPoint Energy Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Read More Five stocks we like better than CenterPoint Energy Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value Want to see what other hedge funds are holding CNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CenterPoint Energy, Inc. (NYSE:CNP – Free Report).

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECetera Investment Advisers Buys 5,788 Shares of Owens Corning Inc $OC

NEXT HEADLINE »Empowered Funds LLC Invests $1.68 Million in PagerDuty $PD

CenterPoint Energy, Inc. (CNP) Q2 2026 Earnings Call July 28, 2026 8:00 AM EDT

Company Participants

Ben Vallejo - Vice President of Investor Relations & Corporate Planning
Jason Wells - President, CEO & Chairman
Christopher Foster - Executive VP & CFO

Conference Call Participants

Shahriar Pourreza - Wells Fargo Securities, LLC, Research Division
Nicholas Campanella - Barclays Bank PLC, Research Division
Julien Dumoulin-Smith - Jefferies LLC, Research Division
Steven Fleishman - Wolfe Research, LLC
Jeremy Tonet - JPMorgan Chase & Co, Research Division
Richard Sunderland - Truist Securities, Inc., Research Division
Sophie Karp - KeyBanc Capital Markets Inc., Research Division
Anthony Crowdell - Mizuho Securities USA LLC, Research Division

Presentation

Operator

Good morning, and welcome to CenterPoint Energy's Second Quarter 2026 Earnings Conference Call with senior management. [Operator Instructions] I will now turn the call over to Ben Vallejo, Vice President of Investor Relations and Corporate Planning. Please go ahead.

Ben Vallejo
Vice President of Investor Relations & Corporate Planning

Good morning, and welcome to CenterPoint's Q2 2026 Earnings Conference Call. Jason Wells, our Chair and CEO; and Chris Foster, our CFO, will discuss the company's second quarter 2026 results. Management will discuss certain topics that will contain projections and other forward-looking information and statements that are based on management's beliefs, assumptions and information currently available to management. These forward-looking statements are subject to risks and uncertainties. Actual results could differ materially based on various factors as noted in our Form 10-Q, other SEC filings and our earnings materials.

We undertake no obligation to revise or update publicly any forward-looking statement other than as required under applicable securities laws. We reported $0.37 per diluted share for the second quarter of 2026 on a GAAP basis. Management will be discussing certain non-GAAP measures on today's call. When providing guidance, we use the non-GAAP EPS measure of diluted adjusted earnings per share on a

3 Data Center Beneficiaries Raising Dividends Up to 60%CenterPoint Energy NYSE: CNP reported second-quarter 2026 GAAP earnings of $0.37 per diluted share and non-GAAP earnings of $0.40 per share, while reaffirming its full-year non-GAAP earnings guidance of $1.89 to $1.91 per share.

Chair and CEO Jason Wells said the midpoint of the guidance range would represent 8% growth from the company’s 2025 delivered results. CenterPoint also reiterated its expectation for non-GAAP earnings-per-share growth at the mid-to-high end of its 7% to 9% annual target range through 2028, followed by 7% to 9% annual growth through 2035.

Get CenterPoint Energy alerts:

The Top 4 Utilities for Value, Yield, and Upside PotentialChief Financial Officer Chris Foster said higher rate recovery added $0.10 per share year over year during the quarter, reflecting updated rates and interim filing mechanisms. Operating and maintenance expense was $0.02 favorable, which Foster attributed to efficiencies in the company’s vegetation-management program. Milder weather in Texas and Indiana reduced results by $0.01 per share, while higher interest expense was also a $0.01 unfavorable factor.

Texas large-load projects advance through ERCOT process CenterPoint said it submitted more than 17 gigawatts of prospective large-load projects through ERCOT’s Batch Zero process. Of those submissions, 14 GW remain eligible for the process, representing more than 65% of Houston Electric’s current 21-GW system peak.

Approximately 10 GW of the eligible projects have both required studies approved and qualify for base-load designation, Wells said. Another 4 GW has one required study approved and may qualify as studied load, subject to ERCOT’s allocation process, which is expected to conclude in April 2027.

The company expects nearly all of the 14 GW of eligible base-load and studied-load projects to be energized by the end of 2030, based on customers’ projected load ramps. Wells said the projects are backed by signed Facilities Extension Agreements, long-term end-user commitments and approximately $900 million of customer cash commitments and security already received.

CenterPoint has begun targeted system-upgrade work for the base-load-eligible projects and expects that work to continue over the next four years. The company said it expects to connect 3 GW in 2027. For later projects, it has begun engineering work and secured long-lead materials, according to Wells.

In addition to transmission-level demand, Wells said Houston Electric is seeing growing distribution-level demand. The company anticipates an additional 2 GW of distribution-level demand over the coming years, driven by advanced manufacturing, population growth and other development in the greater Houston area. During the question-and-answer session, Wells said the 65% growth figure tied to Batch Zero does not include distribution-level customer growth.

Capital plan rises by $1.2 billion CenterPoint increased its 10-year capital investment plan to $66.7 billion from $65.5 billion. The $1.2 billion increase includes $800 million for targeted system upgrades associated with the 14 GW of Batch Zero-eligible projects and $400 million for the Downtown Houston Revitalization Project.

Wells said Houston Electric’s roughly 10 GW of existing hosting capacity allows the company to connect large-load projects with relatively modest incremental investment. CenterPoint estimates the system upgrades can be completed at less than $60 million per gigawatt.

The company also identified approximately $700 million of potential investment opportunities to serve about 3 GW of additional demand that is not currently eligible as base load or studied load in the Batch Zero process. Those investments are not included in the updated capital plan because they remain subject to future batch processes.

Following final site selections for two substation relocations tied to the Downtown Houston project, CenterPoint refined its investment estimate and added $400 million to the plan. The company now expects Houston Electric’s rate base to grow at a compound annual rate of more than 18% over the next three years.

Foster said the revised plan does not require additional equity financing. He cited existing funding capacity following clarification of Corporate Alternative Minimum Tax rules, as well as the expected October 1 closing of the sale of the Ohio Gas local distribution company after regulatory approval. CenterPoint’s planned equity issuance remains unchanged.

The company said potential future financing tailwinds include cash flow from demand charges, potential proceeds or flexibility from marketing temporary generation units, and anticipated tax refunds. CenterPoint expects about $6 million per GW per month in demand-charge cash flow as the expected 14 GW of new load is energized over the next five years. Foster said those cash-flow benefits have not yet been incorporated into the company’s plan.

Customer affordability and Indiana opportunities CenterPoint estimates that the addition of 14 GW of eligible large-load projects in Texas could save residential and commercial electric customers more than $5 billion over the next decade. Foster said the estimate reflects large-load customers absorbing system costs that otherwise would be borne by smaller customers. He described the result as roughly $500 million in annual savings over 10 years.

In Indiana, CenterPoint said it continues to advance a large-load opportunity that could be the single largest load served in its Indiana Electric territory. The company has begun engineering work, ordered long-lead materials and secured a place in the MISO interconnection queue for the project, Wells said.

Wells added that system analysis has identified incremental short- and medium-term capacity that can support discussions with multiple potential customers. CenterPoint has previously estimated that the initial Indiana demand could provide about $250 million in residential customer savings over 15 years.

If Indiana demand exceeds approximately 1.5 GW, Wells said the company could consider pursuing a generation-company structure to support additional generation needs. Investments related to Indiana large-load opportunities would be incremental to CenterPoint’s current base capital plan.

Regulatory and balance-sheet update Foster said CenterPoint recovers approximately 85% of its investments through capital trackers. In Houston Electric, the company filed a distribution capital tracker seeking a $73 million revenue requirement increase, with customer delivery charges expected to be updated in November. It also expects to file a transmission capital tracker next month.

CenterPoint received approval for a Texas Gas capital investment recovery filing seeking approximately $62 million in additional revenue requirement, with rates taking effect in June. The company also plans to file forward-looking rate cases for Minnesota Gas and its North and South Indiana Gas operations by year-end.

CenterPoint invested $1.5 billion during the second quarter and said it had completed about 40% of its planned 2026 capital spending through the first half. The company remains on track to invest $6.8 billion this year.

Its adjusted funds-from-operations-to-debt ratio under Moody’s methodology was 13.4% at the end of the second quarter, nearly 100 basis points higher than in the first quarter. Foster said a portion of an expected Corporate Alternative Minimum Tax refund could add roughly 30 basis points to the metric in the third quarter.

About CenterPoint Energy (NYSE:CNP)CenterPoint Energy, Inc NYSE: CNP is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company's principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint's core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in CenterPoint Energy Right Now?Before you consider CenterPoint Energy, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CenterPoint Energy wasn't on the list.

While CenterPoint Energy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

On July 28, 2026, CenterPoint Energy Inc (CNP) released its 8-K filing, detailing its financial performance for the second quarter of 2026. The company reported

HOUSTON--(BUSINESS WIRE)--CenterPoint Energy, Inc. (NYSE: CNP), or “CenterPoint,” today reported net income of $244 million, or $0.37 per diluted share, on a GAAP basis for the second quarter of 2026, compared to $0.30 per diluted share in the comparable period of 2025. Non-GAAP EPS for the second quarter of 2026 was $0.40 per diluted share, compared to $0.29 per diluted share in the comparable period of 2025. These strong second quarter results were primarily driven by growth and regulatory re.

Key Takeaways CenterPoint Energy's Q2 earnings and revenues are expected to rise year over year.Industrial demand, data centers and electrification may support revenues.Infrastructure returns and rate-base growth may lift earnings, while financing costs weigh. CenterPoint Energy, Inc. (CNP - Free Report) is slated to report second-quarter 2026 results on July 28, 2026, before market open. The company delivered a negative earnings surprise of 3.45% in the last reported quarter.

Let’s discuss the factors that are likely to be reflected in the upcoming quarterly results.

Factors to Consider Ahead of CNP’s Q2 ResultsIncreased capital spending by CenterPoint Energy is likely to have reinforced its infrastructure base and strengthened service reliability. Ongoing investments in transmission and distribution projects, grid modernization and system resiliency initiatives are expected to have enhanced operational efficiency and support the company’s second-quarter results.

Rising electricity demand from industrial customers, expanding data center operations and continued transportation electrification initiatives are likely to have supported the company’s overall revenues in the soon-to-be-reported quarter.

Profitable returns from earlier infrastructure investments, continued rate-base expansion and constructive regulatory recovery mechanisms are likely to have strengthened CenterPoint Energy’s overall earnings performance.

Higher interest expenses and financing costs associated with funding the company’s ongoing capital investment program are likely to have offset some of the positives in the second quarter.

Q2 Expectations for CNPThe Zacks Consensus Estimate for earnings is pegged at 37 cents per share, indicating a year-over-year increase of 27.6%.

The consensus estimate for revenues is pinned at $2.11 billion, implying an 8.7% improvement year over year.

The Zacks Consensus Estimate for the total electric throughput stands at 30,767.7 gigawatt-hours, up 1.5% from the figure registered in the year-ago quarter.

The consensus estimate for total natural gas throughput is pinned at 112.7 billion cubic feet, up 1.5% year over year.

What the Zacks Model Unveils for CNPOur proven model predicts an earnings beat for CenterPoint Energy this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as you will see below.

Earnings ESP: CNP has an Earnings ESP of +1.60%. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Zacks Rank: Currently, CenterPoint Energy carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Other Stocks to ConsiderInvestors may consider the following players from the same industry, as these also have the right combination of elements to post an earnings beat this reporting cycle.

Ameren (AEE - Free Report) is slated to report its second-quarter 2026 results on July 30, after market close. It has an Earnings ESP of +0.19% and a Zacks Rank of 2 at present.

AEE’s long-term (three to five years) earnings growth rate is 7.7%. The Zacks Consensus Estimate for earnings is pegged at $1.08 per share, which suggests a year-over-year rise of 6.9%.

Edison International (EIX - Free Report) is slated to report its second-quarter 2026 results on July 30, after market close. It has an Earnings ESP of +4.66% and a Zacks Rank of 2 at present.

EIX’s long-term earnings growth rate is 2.1%. The Zacks Consensus Estimate for earnings stands at $1.02 per share, which suggests a year-over-year rise of 5.2%.

The Southern Company (SO - Free Report) is scheduled to report its second-quarter 2026 results on July 30, before market open. It has an Earnings ESP of +1.16% and a Zacks Rank of 3 at present.

SO’s long-term earnings growth rate is 11.1%. The Zacks Consensus Estimate for earnings stands at $1.01 per share, which implies a year-over-year increase of 11%.

CenterPoint Energy (CNP - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

As such, the Zacks rating upgrade for CenterPoint is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For CenterPoint, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for CenterPointFor the fiscal year ending December 2026, this energy delivery company is expected to earn $1.91 per share, which is unchanged compared with the year-ago reported number.

Analysts have been steadily raising their estimates for CenterPoint. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.1%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of CenterPoint to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Posted by Defense World Staff on Jul 23rd, 2026

Andra AP fonden purchased a new position in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 103,900 shares of the utilities provider’s stock, valued at approximately $4,484,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in CenterPoint Energy by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 82,381,128 shares of the utilities provider’s stock valued at $3,158,492,000 after acquiring an additional 719,803 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in CenterPoint Energy by 13.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 58,286,690 shares of the utilities provider’s stock worth $2,234,712,000 after purchasing an additional 6,794,535 shares in the last quarter. Capital Research Global Investors grew its stake in shares of CenterPoint Energy by 1.1% during the 4th quarter. Capital Research Global Investors now owns 20,941,909 shares of the utilities provider’s stock worth $802,916,000 after purchasing an additional 235,346 shares during the period. Geode Capital Management LLC grew its stake in shares of CenterPoint Energy by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 17,023,720 shares of the utilities provider’s stock worth $650,189,000 after purchasing an additional 166,305 shares during the period. Finally, Norges Bank purchased a new position in shares of CenterPoint Energy during the 4th quarter valued at approximately $343,925,000. Hedge funds and other institutional investors own 91.77% of the company’s stock.

Analyst Ratings Changes CNP has been the subject of several analyst reports. Wall Street Zen cut shares of CenterPoint Energy from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Barclays raised their price target on shares of CenterPoint Energy from $38.00 to $44.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 15th. Evercore set a $45.00 price objective on shares of CenterPoint Energy in a research report on Monday, May 4th. Bank of America lifted their price target on CenterPoint Energy from $42.00 to $44.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Finally, Truist Financial lowered their price target on CenterPoint Energy from $48.00 to $47.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Eight investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $45.46.

Check Out Our Latest Stock Analysis on CNP

CenterPoint Energy Price Performance Shares of CenterPoint Energy stock opened at $43.71 on Thursday. The stock has a market capitalization of $28.60 billion, a P/E ratio of 26.82, a PEG ratio of 2.53 and a beta of 0.46. The business has a 50 day simple moving average of $43.06 and a two-hundred day simple moving average of $42.24. CenterPoint Energy, Inc. has a 12 month low of $36.59 and a 12 month high of $45.22. The company has a debt-to-equity ratio of 1.96, a current ratio of 1.16 and a quick ratio of 1.04.

CenterPoint Energy (NYSE:CNP – Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The utilities provider reported $0.56 EPS for the quarter, missing the consensus estimate of $0.58 by ($0.02). CenterPoint Energy had a return on equity of 10.56% and a net margin of 11.38%.The firm had revenue of $2.98 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the previous year, the firm posted $0.53 earnings per share. As a group, analysts predict that CenterPoint Energy, Inc. will post 1.91 EPS for the current fiscal year.

CenterPoint Energy Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Thursday, August 20th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, August 20th. This is a positive change from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 dividend on an annualized basis and a dividend yield of 2.2%. CenterPoint Energy’s payout ratio is currently 56.44%.

CenterPoint Energy Company Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Further Reading Five stocks we like better than CenterPoint Energy Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Sells 77,228 Shares of Invitation Home $INVH

NEXT HEADLINE »ABN Amro Investment Solutions Sells 12,387 Shares of Air Products and Chemicals, Inc. $APD

Wall Street expects a year-over-year increase in earnings on higher revenues when CenterPoint Energy (CNP - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on July 28, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis energy delivery company is expected to post quarterly earnings of $0.36 per share in its upcoming report, which represents a year-over-year change of +24.1%.

Revenues are expected to be $2.11 billion, up 8.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CenterPoint?For CenterPoint, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.07%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that CenterPoint will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CenterPoint would post earnings of $0.58 per share when it actually produced earnings of $0.56, delivering a surprise of -3.45%.

Over the last four quarters, the company has beaten consensus EPS estimates just once.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CenterPoint appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

, /PRNewswire/ -- CenterPoint Energy, Inc.'s (NYSE: CNP) Board of Directors yesterday declared a regular quarterly cash dividend of $0.2400 per share on the issued and outstanding shares of Common Stock payable on September 10, 2026, to shareholders of record at the close of business on August 20, 2026. This represents a $0.0100 increase over the April 2026 declared dividend per share and in line with CenterPoint's targeted annual dividend per share growth rate of 6%.

About CenterPoint Energy, Inc.  

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of March 31, 2026, the company owned approximately $48 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

Forward-Looking Statement
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this news release, the words "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "objective," "plan," "potential," "predict," "projection," "should," "target," "will" or other similar words are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding our strategic, growth and capital plans, longer-term resiliency plans, and future performance and financial results, are based upon assumptions of management which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. Actual events and results may differ materially from those expressed or implied by these forward-looking statements. Any statements in this news release regarding future events that are not historical facts are forward-looking statements. Each forward-looking statement contained in this news release speaks only as of the date of this release or the date that such statement is made, as applicable. Important factors that could cause actual results to differ materially from those indicated by the provided forward-looking information include risks and uncertainties relating to: (1) business strategies and strategic initiatives; (2) CenterPoint Energy's ability to fund and invest planned capital, and the timely recovery of its investments; (3) financial market and general economic conditions; (4) the timing and impact of future regulatory, legislative and political actions or developments; and (5) other factors, risks and uncertainties discussed in CenterPoint Energy's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, Form 10-Q for the fiscal quarter ended March 31, 2026 and other reports CenterPoint Energy or its subsidiaries may file from time to time with the Securities and Exchange Commission.

[email protected]

SOURCE CenterPoint Energy, Inc

June 30, 2026 08:30 ET  | Source: Ascendis Pharma

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA). As previously reported, improvements in annualized growth velocity were maintained and ACH-specific height Z-score increased with TransCon CNP treatment through Week 104. The data were presented by Leanne M. Ward, M.D., FRCPC, Professor of Pediatrics at the University of Ottawa and Children's Hospital of Eastern Ontario, during the 12th International Conference on Children's Bone Health (ICCBH 2026) held in Montreal, Canada.

“These results show that continuous exposure to active C-type natriuretic peptide (CNP) provided by once-weekly TransCon CNP positively affected skeletal growth and lower limb alignment in children with achondroplasia, with the potential to address serious complications of skeletal dysplasia that contribute to chronic pain, altered mobility, and need for surgical intervention,” said Dr. Ward. “These outcomes reinforce previously reported data showing TransCon CNP’s ability to support healthy and proportional growth, further highlighting its potential to advance pharmacological treatment for achondroplasia.”

ApproaCH Trial Design
ApproaCH was a randomized, double-blind, placebo-controlled pivotal trial in 84 children with achondroplasia aged 2–11 years, investigating TransCon CNP (100 µg/kg once-weekly) versus placebo for 52 weeks, followed by an open-label extension (OLE) in which all participants received TransCon CNP through Week 104. Radiographic assessments of lower extremity alignment were conducted at baseline, Week 52, and Week 104.

Highlights of Radiographic Assessments at Week 104 of the Pivotal ApproaCH Trial

Improvements in TFA and TFA Z-scores continued through Week 104 and were greater in children with baseline TFA ≥ 5°: The average TFA in all children treated with TransCon CNP during the double-blind period was 9.1° at baseline, decreasing to 7.7° at Week 52 and 6.9° at Week 104, reflecting a mean absolute change of -2.2 degrees over the two-year treatment period. In the subgroup of children with baseline TFA ≥ 5° (reflecting children with preexisting genu varum), the average TFA was 13.4° at baseline, decreasing to 11.3° at Week 52 and 9.6° at Week 104, reflecting a mean absolute change of -3.8 degrees over the two-year treatment period.The average TFA in children switching from placebo to TransCon CNP treatment at Week 52 was 11.5° at baseline, increasing to 11.8° at Week 52 and decreasing with TransCon CNP treatment to 10.1° at Week 104, reflecting a mean absolute change of -1.7 degrees during the OLE period. In the subgroup of children with baseline TFA ≥ 5°, the average TFA was 18.2° at baseline, increasing to 18.7° at Week 52 and decreasing with treatment to 14.9° at Week 104, reflecting a mean absolute change of -3.8 degrees during the OLE period.In children treated with TransCon CNP in the double-blind period, mean TFA Z-score was 3.62 at baseline and decreased to 3.15 at Week 52 and 2.96 at Week 104, reflecting a mean absolute change of -0.66 over the two-year treatment period. In the subgroup of children with baseline TFA ≥ 5°, mean TFA Z-score was 5.40 at baseline and decreased to 4.67 at Week 52 and 4.36 at Week 104, reflecting a mean absolute change of -1.04 over the two-year treatment period.In children switching from placebo to TransCon CNP at Week 52, mean TFA Z-score was 4.08 at baseline, increased to 4.76 at Week 52, and decreased to 4.28 at Week 104, reflecting a mean absolute change of -0.48 from Week 52 to Week 104. In the subgroup of children with baseline TFA ≥ 5°, mean TFA Z-score was 6.13 at baseline, increased to 7.56 at Week 52, and decreased to 6.35 at Week 104, reflecting a mean absolute change of -1.21 from Week 52 to Week 104. Results also showed that fibula-to-tibia length ratio remained stable in the overall clinical trial population during the open-label extension, reflecting proportional growth of the lower leg. Through up to two years of treatment, TransCon CNP was generally well tolerated, with a low rate of ISRs (all mild), no symptomatic hypotension, and no acceleration of bone age. Most adverse events in TransCon CNP-treated children were mild or moderate, with none leading to treatment discontinuation or withdrawal from the trial.

A slide presentation with these data will be made available on the Investors & News section of the Ascendis Pharma website: https://investors.ascendispharma.com.

About TransCon CNP
TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, and is associated with an increased risk of muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia can vary from individual to individual and across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and reduced stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; some of which persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) TransCon CNP’s ability to address serious complications of skeletal dysplasia, including those that contribute to chronic pain, altered mobility, and need for surgical intervention, (ii) TransCon CNP’s ability to deliver healthy and proportional growth and its potential to advance pharmacological treatment of achondroplasia, (iii) the anticipated timing of a regulatory decision by the European Medicines Agency regarding YUVIWEL, (iv) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (v) Ascendis’ use of TransCon to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YUVIWEL® are trademarks owned by the Ascendis Pharma group. © June 2026 Ascendis Pharma A/S.

Investor Contacts:Media Contact:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875

, /PRNewswire/ -- CenterPoint Energy, Inc.'s (NYSE: CNP) Board of Directors today declared a regular quarterly cash dividend of $0.2300 per share on the issued and outstanding shares of Common Stock payable on June 11, 2026, to shareholders of record at the close of business on May 21, 2026.

About CenterPoint Energy, Inc. 
CenterPoint Energy, Inc. (NYSE: CNP) is a multi-state electric and natural gas delivery company serving approximately 7 million metered customers across Indiana, Minnesota, Ohio, and Texas. The company is headquartered in Houston and is the only Texas-domiciled investor-owned utility. As of December 31, 2024, the company had approximately $44 billion in assets. With approximately 8,300 employees, CenterPoint Energy and its predecessor companies have been serving customers for more than 150 years. For more information, visit CenterPointEnergy.com.

Forward-Looking Statement
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this news release, the words "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "objective," "plan," "potential," "predict," "projection," "should," "target," "will" or other similar words are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding our strategic, growth and capital plans, longer-term resiliency plans, and future performance and financial results, are based upon assumptions of management which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. Actual events and results may differ materially from those expressed or implied by these forward-looking statements. Any statements in this news release regarding future events that are not historical facts are forward-looking statements. Each forward-looking statement contained in this news release speaks only as of the date of this release or the date that such statement is made, as applicable. Important factors that could cause actual results to differ materially from those indicated by the provided forward-looking information include risks and uncertainties relating to: (1) business strategies and strategic initiatives; (2) CenterPoint Energy's ability to fund and invest planned capital, and the timely recovery of its investments; (3) financial market and general economic conditions; (4) the timing and impact of future regulatory, legislative and political actions or developments; and (5) other factors, risks and uncertainties discussed in CenterPoint Energy's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other reports CenterPoint Energy or its subsidiaries may file from time to time with the Securities and Exchange Commission. 

For more information, contact
Communications
[email protected]

SOURCE CenterPoint Energy

Posted by Defense World Staff on Apr 20th, 2026

KBC Group NV boosted its holdings in CenterPoint Energy, Inc. (NYSE:CNP – Free Report) by 40.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 83,207 shares of the utilities provider’s stock after purchasing an additional 23,980 shares during the period. KBC Group NV’s holdings in CenterPoint Energy were worth $3,190,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CNP. LBP AM SA raised its stake in shares of CenterPoint Energy by 12.2% during the 4th quarter. LBP AM SA now owns 93,878 shares of the utilities provider’s stock worth $3,599,000 after purchasing an additional 10,197 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of CenterPoint Energy by 4.0% in the 4th quarter. Farther Finance Advisors LLC now owns 15,948 shares of the utilities provider’s stock worth $611,000 after buying an additional 617 shares during the last quarter. Sage Mountain Advisors LLC grew its position in CenterPoint Energy by 75.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 9,463 shares of the utilities provider’s stock valued at $363,000 after buying an additional 4,072 shares during the period. Tectonic Advisors LLC grew its position in CenterPoint Energy by 5.4% during the fourth quarter. Tectonic Advisors LLC now owns 15,112 shares of the utilities provider’s stock valued at $579,000 after buying an additional 771 shares during the period. Finally, Baillie Gifford & Co. increased its holdings in CenterPoint Energy by 5.4% during the fourth quarter. Baillie Gifford & Co. now owns 400,829 shares of the utilities provider’s stock worth $15,368,000 after buying an additional 20,502 shares during the last quarter. Institutional investors own 91.77% of the company’s stock.

Analyst Ratings Changes Several analysts have commented on CNP shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of CenterPoint Energy in a research report on Monday, December 29th. Wells Fargo & Company increased their target price on shares of CenterPoint Energy from $44.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. BMO Capital Markets upgraded shares of CenterPoint Energy from a “market perform” rating to an “outperform” rating and set a $42.00 price target for the company in a research note on Tuesday, January 13th. Barclays lifted their price target on shares of CenterPoint Energy from $38.00 to $44.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, Jefferies Financial Group increased their price objective on CenterPoint Energy from $44.00 to $49.00 and gave the company a “buy” rating in a report on Thursday. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $43.75.

View Our Latest Stock Report on CenterPoint Energy

CenterPoint Energy Price Performance NYSE CNP opened at $43.03 on Monday. The company has a quick ratio of 0.79, a current ratio of 0.91 and a debt-to-equity ratio of 1.84. The company has a market cap of $28.15 billion, a PE ratio of 26.89, a price-to-earnings-growth ratio of 2.55 and a beta of 0.54. CenterPoint Energy, Inc. has a 52 week low of $35.46 and a 52 week high of $44.47. The firm’s 50-day simple moving average is $42.91 and its two-hundred day simple moving average is $40.40.

CenterPoint Energy (NYSE:CNP – Get Free Report) last posted its earnings results on Thursday, February 19th. The utilities provider reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.01). CenterPoint Energy had a return on equity of 10.46% and a net margin of 11.24%.The business had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.23 billion. During the same quarter in the previous year, the business earned $0.40 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.900- EPS. Research analysts predict that CenterPoint Energy, Inc. will post 1.75 earnings per share for the current year.

CenterPoint Energy Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Thursday, May 21st will be paid a $0.23 dividend. This represents a $0.92 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Thursday, May 21st. CenterPoint Energy’s payout ratio is currently 57.50%.

CenterPoint Energy Company Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Featured Stories Five stocks we like better than CenterPoint Energy

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEEmissary Wealth LLC Acquires New Holdings in Oracle Corporation $ORCL

NEXT HEADLINE »KBC Group NV Trims Stake in Ralph Lauren Corporation $RL

HOUSTON--(BUSINESS WIRE)--CenterPoint Energy, Inc. (NYSE: CNP), or “CenterPoint,” today reported net income of $316 million, or $0.48 per diluted share, on a GAAP basis for the first quarter of 2026, compared to $0.45 per diluted share in the comparable period of 2025. Non-GAAP EPS for the first quarter of 2026 was $0.56, compared to $0.53 per diluted share in the comparable period of 2025. These strong first-quarter results were primarily driven by growth and regulatory recovery, which contrib.

Key Takeaways CNP reported Q1 adjusted EPS of 56 cents, missing estimates, though up 5.7% year over year.CenterPoint Energy posted $2.98B revenues, missing estimates but rising 2% from last year.CNP raised its 10-year capital plan to $65.5B and expects major data center load growth by 2029. CenterPoint Energy, Inc. (CNP - Free Report) reported first-quarter 2026 adjusted earnings of 56 cents per share, which missed the Zacks Consensus Estimate of 58 cents by 3.8%. However, the bottom line increased 5.7% from 53 cents in the year-ago quarter.

The company recorded GAAP earnings of 48 cents per share compared with 45 cents in the first quarter of 2025.

CNP’s RevenuesCNP generated revenues of $2.98 billion, which missed the Zacks Consensus Estimate of $3.04 billion by 1.4%. However, the top line improved 2% from the year-ago reported figure of $2.92 billion.

Highlights of CNP’s Q1 ReleaseTotal expenses increased 2% year over year to $2.32 billion.

CNP reported an operating income of $658 million compared with $649 million in the previous year.

Interest expenses and other finance charges totaled $265 million, up 13.2% from $234 million last year.

The company announced 12.2 gigawatts (GW) of firmly committed industrial load at Houston Electric, expecting 8 GW of data center load to be energized by 2029.

CNP’s Financial ConditionAs of March 31, 2026, CenterPoint Energy had cash and cash equivalents of $639 million compared with $38 million as of Dec. 31, 2025.

As of the aforementioned date, total long-term debt was $22.5 billion compared with $20.6 billion as of Dec. 31, 2025.

Net cash flow from operating activities during the first three months of 2026 amounted to $282 million compared with $410 million in the year-ago period.

The total capital expenditure for the quarter was $1.2 billion compared with $1.04 billion a year ago.

CNP’s 2026 GuidanceCenterPoint Energy has reiterated its 2026 non-GAAP EPS guidance of $1.89-$1.91, the midpoint of which would represent 8% growth over 2025 delivered results. The Zacks Consensus Estimate for earnings is pegged at $1.91 per share, which is the top end of the company’s guided range.

The company announced a $500 million increase to its 10-year capital plan, bringing total capital expenditures to nearly $65.5 billion through 2035.

CNP’s Zacks RankThe company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Upcoming Utility ReleasesEdison International (EIX - Free Report) is scheduled to report first-quarter results on April 28, after market close. The Zacks Consensus Estimate for earnings is pegged at $1.71 per share, which suggests a year-over-year increase of 24.8%.

EIX’s long-term (three to five years) earnings growth rate is 9.43%. The Zacks Consensus Estimate for first-quarter sales is pinned at $3.85 billion, which implies a year-over-year improvement of 1.1%.

Alliant Energy (LNT - Free Report) is slated to report first-quarter results on April 30, after market close. The Zacks Consensus Estimate for earnings is pegged at 83 cents per share, flat year over year.

LNT’s long-term earnings growth rate is 7.15%. The Zacks Consensus Estimate for first-quarter sales is pinned at $1.17 billion, which implies year-over-year growth of 3.9%.

Public Service Enterprise Group (PEG - Free Report) is slated to report first-quarter results on May 5, before market open. The Zacks Consensus Estimate for earnings is pegged at $1.50 per share, which implies a year-over-year increase of 4.9%.

PEG’s long-term earnings growth rate is 7.05%. The Zacks Consensus Estimate for first-quarter sales is pinned at $3.28 billion, which implies a year-over-year rise of 1.9%.

CenterPoint Energy, Inc. (CNP) Q1 2026 Earnings Call Transcript

May 06, 2026 16:01 ET  | Source: Ascendis Pharma

COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly TransCon CNP (navepegritide) in its pivotal ApproaCH Trial demonstrated significantly greater annualized growth velocity (AGV) compared to placebo at Week 52, and sustained these growth improvements through up to two years of treatment. The safety profile for this subgroup through up to two years of treatment was similar to the overall population, with a low rate of injection site reactions (ISRs, all mild), no symptomatic hypotension, and no acceleration of bone age. The data follow previously reported Week 104 results showing consistent improvements in growth and body proportionality in the overall population, and expand on data recently presented by M. Jennifer Abuzzahab, M.D. during PES 2026, the annual meeting of the Pediatric Endocrine Society.

“We are pleased to see confirmation of the expected sustained growth improvements in these children, with a consistent safety and tolerability profile,” said Aimee D. Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma. “These results, along with the improved skeletal alignment and body proportionality and positive changes in health-related quality of life previously reported for the overall populationi further highlight TransCon CNP’s ability to promote healthy, proportional growth in children with achondroplasia across age groups.”

ApproaCH Trial Design
ApproaCH was a randomized, double-blind, placebo-controlled pivotal trial in 84 children with achondroplasia aged 2–11 years, investigating TransCon CNP (100 µg/kg once-weekly) versus placebo for 52 weeks, followed by a 52-week open-label extension (OLE) period in which all participants received TransCon CNP through Week 104. Fifty-three of the 84 children were ≥5 years of age at the time of their enrollment in the trial.

Highlights of the ApproaCH Trial Data Through Week 104
Subgroup of children aged ≥5 years at enrollment

 AGV (cm/year) LS MeanObserved Mean3 Week 52Week 52Week 104TransCon CNP(n=36)5.795.845.71Placebo/TransCon CNP1 (n=17)4.023.885.53TransCon CNP vs. Placebo, Treatment Difference
[95% CI]+1.78
[1.22, 2.33]
p<0.0001+1.972
[1.37, 2.56]
p<0.0001-
 ACH-Specific Height Z-score,
Change from BaselineCDC-Based Height Z-score,
Change from BaselineLS MeanObserved Mean3LS MeanObserved Mean3Week 52Week 52Week 104Week 52Week 52Week 104TransCon CNP (n=36)+0.38+0.38+0.75+0.28+0.26+0.58Placebo/TransCon CNP1 (n=17)+0.07+0.07+0.46-0.05-0.02+0.36TransCon CNP vs. Placebo, Treatment Difference2
[95% CI]+0.31
[0.20, 0.42]
p<0.0001+0.30
[0.18, 0.42]
p<0.0001-
+0.32
[0.20, 0.44]
p<0.0001+0.29
[0.14, 0.44]
p=0.0004-
        Note: The observed mean is a simple average of recorded measurements; the LS mean is a model-based estimated average that adjusts for selected variables, typically baseline patient characteristics, enabling a more balanced comparison across arms of a clinical trial.
1 Week 104 data reflects placebo patients that crossed over to TransCon CNP treatment at Week 52
2 Not presented at PES 2026; included for context
3 Treatment differences between TransCon CNP and placebo were estimated from a T-test

Through up to two years of treatment, the safety profile in children ≥5 years was similar to the overall population, with a low rate of ISRs (all mild), no symptomatic hypotension, and no acceleration of bone age. Most adverse events in TransCon CNP-treated children were mild or moderate, with none leading to treatment discontinuation or withdrawal from the trial.

A slide presentation with these data can be found on the Investor Relations & News section of the Ascendis Pharma website: https://investors.ascendispharma.com.

About TransCon CNP
TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, and is associated with an increased risk of muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia can vary from individual to individual and across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and reduced stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; some of which persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) TransCon CNP’s ability to promote healthy, proportional growth in children with achondroplasia across age groups, (ii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (iii) Ascendis’ use of TransCon to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, TransCon, and YUVIWEL® are trademarks owned by the Ascendis Pharma group. © May 2026 Ascendis Pharma A/S.

Investor Contact:Media Contact:Chad FugereMelinda BakerAscendis Pharma Ascendis Pharma+1 (650) 519-7494+1 (650) 709-8875

CenterPoint Energy is rated a "Buy," driven by its robust Texas-focused growth pipeline and strong earnings outlook. CNP targets 7%-9% annual EPS growth through 2035, supported by rapid population gains, industrial demand, and a favorable regulatory environment. Despite ongoing equity issuance to fund a $65.5 billion cap-ex plan, CNP expects to deliver 8%-9% EPS growth and a 2.2% dividend yield.